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Abstract 
Hematopoietic stem cell (HSC) chemotaxis,
adhesion, proliferation, quiescence and differ-
entiation  are  regulated  by  interactions  with
bone marrow (BM) niches. Two niches have
been identified in the adult BM: the endosteal
(close to the bone) and the perivascular niche
(close to blood vessels). A vast body of litera-
ture has revealed the molecular basis for the
interaction  of  HSCs  with  the  two  niches.
However, the signals that regulate the commu-
nication between the two niches have not been
well defined. Taking in consideration several
clinical  and  experimental  arguments  this
review highlights the molecular cues, involved
in the communication between the BM niches,
which regulate the basic properties of HSCs in
physiological  and  malignant  conditions.  As
such, it aims at clarifying the most important
advances in basic and clinical research focus-
ing on the role of different factors in the regu-
lation of the BM microenvironment.
Introduction
Hematopoietic stem cells reside in bone
marrow niches, which regulate their fate
Hematopoietic stem cells (HSCs) are self-
renewing cells which give rise to all types of
mature  blood  cells.  HSCs  can  be  subdivided
into long-term HSCs (LT-HSCs) and in short-
term (ST-HSCs). LT-HSCs can give rise to all
blood lineages and have unlimited self-renew-
al capacity. LT-HSCs produce ST-HSCs which
are  still  multipotent  but  with  limited  self-
renewal  capacity.  ST-HSCs  differentiate  fur-
ther  into  lineage-committed  progenitor  cells
which are responsible for the large-scale pro-
duction of mature blood cells.
1
The bone marrow (BM) is the major site of
adult hemopoiesis, but, in pathological condi-
tions,  hemopoiesis  can  also  occur  in  extra-
medullary sites like thymus, spleen and liver.
HSCs are localized in specialized microenvi-
ronments within hematopoietic tissues called
niches.
2-6 Within the BM, two anatomical and
functional  niches  have  been  proposed,  the
endosteal niche
7-10 and the perivascular niche.
11
It has been suggested that about 60% of bone-
marrow  HSCs  are  adjacent  to  perivascular
niches and up to 20% of HSCs localize in the
endosteal  niches;  the  remaining  HSCs  are
believed to be scattered throughout the BM.
11,12
Endosteal niches, located at the inner bone
surface,  contain  quiescent  HSCs,  character-
ized by a low proliferative rate; whereas acti-
vated HSCs, which undergo differentiation and
ultimately mobilization to the peripheral circu-
lation, are in close contact to sinusoids of the
BM  microvasculature  in  the  perivascular
niche
10,13-18 Endosteal  niches  may  thus  repre-
sent  a  reserve  of  HSCs,  while  perivascular
niches connect HSCs to the blood stream. 
The  endosteal  niche  mainly  comprises
endosteal  cells,  osteoblasts  and  osteoclasts,
while the perivascular niche contains mainly
endothelial cells. Stromal cells, including retic-
ular and mesenchymal cells, are common com-
ponents  of  both  niches.  They  are  scattered
throughout the trabecular space of the BM and
surround the endothelial cells. As these cells
are a component of both endosteal and vascu-
lar niches, they may serve as a cellular link
between  them.
15 The  cellular  components  of
the niches interact with each other to support
HSC adhesion, quiescence, chemotaxis and, in
the  case  of  the  vascular  niche,  differentia-
tion.
10,14,16,17,19-21 Thus,  the  HSC  properties  and
functional responses depend on specific inter-
action with BM niches (Table 1).
Chemotaxis
Bone marrow niches recruit hematopoietic
stem cells
HSC  chemotaxis  towards  the  endosteal
niche has been suggested to be mediated by
osteoponin (Opn) and calcium ion concentra-
tion ([Ca
2+]o).
25 Opn, a glycoprotein expressed
on endosteal bone surface by osteoblasts, pro-
motes HSC migration, as shown in vivo stud-
ies with Opn
-/- mice. In these mice, there is a
long-term engraftment defect after transplan-
tation with wild-type Lineage
–Sca
–1
+c-Kit
+ cells
and  a  compromised  ability  of  the  Opn
-/- BM
microenvironment  to  sustain  hematopoiesis.
These effects seem to be indirect, since there
is no evidence, in vitro, of a chemotactic role
for Opn on HSCs. Moreover, the high extracel-
lular  [Ca
2+]
o,  maintained  by  the  osteoclasts
activity,  promotes  HSC  localization  to  the
endosteal  niche,  through  calcium-sensing
receptor (CaR): CaR
-/- HSCs show a defect in
the  binding  to  collagenase  I  present  at  the
bone endosteal surface.
Migration of HSCs from the endosteal to the
perivascular niche is regulated by c-kit/Stem
Cell Factor (SCF); CXC chemokine receptor 4
(CXCR4)/stromal-cell derived factor-1 (SDF-1)
and granulocyte colony-stimulating factor (G-
CSF),  pathways.
7,22-24,42 Endothelial  cells  and
reticular  cells  have  been  shown  to  produce
SDF-1, generating a gradient from the perivas-
cular to the endosteal niche, which may thus
promote  HSCs  migration,  since  CXCR4  is
expressed  on  HSC.
22-24 Mobilization  of  HSCs
from  the  endosteal  to  the  vascular  niche  is
essential  for  hemopoietic  recovery  following
myeloablation. In this case, the soluble form of
membrane  stem  cell  factor  (sSCF),  released
from  osteoblasts  after  cleavage  by  SDF-1-
induced matrix metalloproteinase-9, promotes
HSC homing to the perivascular niche by inter-
acting  with  its  receptor  c-Kit.
7,22 G-CSF,  pro-
duced by osteoblasts, promotes the mobiliza-
tion of HSCs into the peripheral blood by up-
regulating  CXCR4  expression  on  HSCs  and
decreasing  SDF-1  expression  in  the  BM.  G-
CSF, in fact, induces the expression of prote-
olytic enzymes such as elastase, cathepsin G,
MMP-2, and MMP-9, which cleave SDF-1.
42,43
Adhesion
Bone marrow niche promotes hematopoietic
stem cells adhesion
HSC adhesion to the endosteal niche is reg-
ulated  by  different  molecular  interactions
including  N-cadherin/β-catenin;  Tie-2/Angio-
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poietin-1 (Ang-1); Osteopontin (Opn)/ß1 inte-
grin;  Annexin  II  (Anxa2)/Anxa2  receptor
(Anxa2r) and CaR-collagen I pathways.
10,25,28,33
The  asymmetrical  distribuition  of  N-
cadherin/β-catenin on the cell surface of HSCs
and osteoblasts, respectively, and, in particu-
lar, the localization of these molecules at the
site  of  interaction  of  LT-HSC  with  spindle-
shaped N-cadherin
+CD45
– osteoblastic (SNO)
cells,  suggested  a  role  for  N-cadherin/ß-
catenin  in  HSCs  adhesion  on  the  endosteal
niches.
10 Studies performed by Kiel and collab-
orators failed to show significant numbers of
N-cadherin  expressing  HSCs,  questioning
whether HSC adhesion to osteoblasts is medi-
ated by N-cadherin.
44
Tie2, a receptor tyrosine kinase expressed
by a small fraction of BM cells highly enriched
for HSC activity in adult murine BM, binds its
ligand, Ang-1, expressed by osteoblasts at the
surface of trabecular bone.
33 Regarding Opn,
its  expression  is  restricted  to  the  endosteal
bone surface and contributes to HSCs adhe-
sion to the endosteal region via ß1 integrin
expressed by HSC.
25 Osteoblasts also express
high  levels  of  Anxa2,  a  calcium-dependent
phospholipid-binding protein, and it has been
shown, both in vitro and in vivo, that Anxa2
regulates  HSCs  homing  and  binding  to  the
endosteal niche, through the binding to its lig-
and Anxa2r.
28
Adhesion of HSCs to the perivascular niche
is mediated by α4β1integrin/vascular cell adhe-
sion  molecule1  (VCAM1)  and  α4/E-selectin
interaction.
26,27,45 α4β1 integrins,  expressed  by
HSCs,  interact  with  VCAM-1,  constitutively
expressed  on  BM  endothelial  cells.
26 Since
inactivation  of  E-selectin  and  α4 integrin
reduces  drastically  hematopoietic  progenitor
and  stem  cell  (HPSC)  homing  into  lethally
irradiated mice, it has been proposed that E-
selectin ligands and α4 integrin cooperate in
HSC adhesion to perivascular niches.
27
Proliferation versus quiescence
Endosteal niches promote HSC quiescence
The balance between HSC proliferation and
quiescence  is  likewise  regulated  by  several
pathways. In the endosteal niche several inter-
actions, involved in the maintenance of HSC
quiescence,  have  been  identified:  Tie-
2/Angiopoietin-1  (Ang-1);  thrombopoietin
(THPO)/MPL; Opn/OpnR; parathyroid hormone
(PTH)/PTH  receptor  (PTHr)  and
Notch1/Jagged1.
14,25,29,33-35,37,46 Tie2,  which  is
expressed by SP-HSCs, binds Ang-1
+ expressed
on osteoblasts and induces HSC quiescence.
33,34
LT-HSCs expressing MPL, the THPO receptor,
are  closely  associated  with  THPO-producing
osteoblasts.  The  THPO/MPL  pathway  is
involved in HSC quiescence through activation
of genes coding for negative regulators of cell
cycle, such as p12
Cip1 and p57
Kip2, and inhibition
of  positive  regulators,  such  as  c-myc.
46 This
pathway is also involved in promoting HSCs
proliferation  in  the  perivascular  niche.
30-32
Thus, THPO/MPL pathway exerts distinct func-
tions on HSC, depending on cell localization.
Opn/OpnR, instead, contributes to the mainte-
nance of HSC quiescence either by inhibiting,
in a dose-dependent manner, the entry into cell
cycle  and/or  by  reducing  cell  apoptosis.
25,29 A
mouse genetic model, in which the gene PTHr
is constitutively active in osteoblasts, showed
an increase in HSCs along with osteoblasts.
Moreover, there was high expression of Notch
I  ligand,  Jagged,  on  osteoblasts,  suggesting
that the PTH/PTHr pathway can promote HSC
proliferation  through  activation  of  Notch.
14,37
Several gain- and loss-of-function experiments
of Notch target genes and ligands have sug-
gested a role for Notch in HSC quiescence and
self-renewal.
35 However, recently Maillard et al.
have  demonstrated  rather  conclusively  that
inactivation  of  the  Notch  pathway  in  HSCs
does  not  interfere  with  their  self-renewal;
transplantation  of  hematopoietic  progenitors
with inhibited Notch signaling induced stable
long-term  reconstitution  of  irradiated  hosts
and a normal frequency of progenitor fractions
enriched for LT-HSCs.
36
Perivascular niches promote hematopoietic
stem cells proliferation and self-renewal
In the vascular niche, HSC proliferation is
associated  with  (THPO)/c-mpl  and  Wnt/β
catenin  pathway.  THPO  is  expressed  on  BM
stromal cells and acts synergistically with ery-
thropoietin  to  promote  erythroid  progenitors
and megakaryocytes proliferation. THPO stim-
ulates  c-myc mRNA  expression  through  a
PI3K- and MAPK-dependent pathway, thereby
promoting HSC proliferation.
30-32 Wnt proteins
are expressed by BM stromal cell and exposure
to Wnt was shown to stimulate proliferation
and self-renewal of HSCs in vitro.
47,48
Differentiation
Perivascular niches mediate hematopoietic
stem cell differentiation
Differentiation of HSCs occurs only in the
perivascular niches and is mediated by FGF-4;
SDF-1; VCAM-1/α4ß ; VE-cadherin and Notch1
pathway.
13,38,39,49 SDF-1  is  necessary  for
myelopoiesis and B-lymphopoiesis, as shown
by  the  severe  reduction  of  B-lymphopoiesis
and lack of BM myelopoiesis in CXCR4- and
SDF-1 deficient mice.
49 SDF-1 and FGF-4 pro-
mote megakaryocyte maturation and platelet
production:  FGF-4  supports  the  adhesion  of
megakaryocytes to sinusoidal BM endothelial
cells (BMECs), thereby enhancing their sur-
vival and maturation, while SDF-1 augments
platelet production by promoting their migra-
tion across BMECs.
13,38 VCAM-1 enhances the
interaction of α4ß1 integrin 
+ megakaryocytes
with  BMECs.  VE-cadherin  is  essential  for
VCAM-1 expression in BMECs, which in turn is
required  for  FGF-4  mediated  adhesion  and
SDF-1-induced  transendothelial  migration  of
megakaryocytes.  Neutralizing  antibodies  to
VE-cadherin  decrease  the  localization  of
megakaryocytes to the vascular niche and dis-
rupt  megakaryocyte  maturation  and  throm-
bopoiesis.
13 Notch1 seems to provide a key reg-
Article
Table 1. HSC properties are regulated by molecular cues conveyed by the bone marrow
endosteal and vascular niches.
HSC properties Molecular interactions
HSC-NICHE
Endosteal niche Perivascular niche
Chemotaxis CXCR4/SDF-1
22-24
Opn
25 G-CSF
22
CaR/Ca
2
c-Kit/SCF
22
Adhesion N-cadherin/ß-catenin
10 α4ß1 integrin/VCAM1
26
Tie2/Ang1
10 α4 integrins/E-selectin
27
ß1 integrin/Opn
25
Anxa2/Anxa2r 
28
CaR/Collagen I
25
Quiescence / proliferation MPL/THPO 
29-32
Tie2/Ang1
33,34
Notch1/Jagged1
35,36 wnt/βcatenin
47,48
Opn
25,29
PTH/PTHr
14,37
Differentiation FGF-4
13
SDF-1/CXCR4
38
α4ß1 integrin/VCAM
13
VE-Cadherin
13
Notch1/Delta
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ulatory signal in determining T- versus B-lym-
phoid lineage commitment. Mice transplanted
with BM, transfected for retroviruses encoding
a constitutively active form of Notch1, three
weeks after transplantation showed immature
CD4
+CD8
+ T cells in the BM and a block in
early B-cell lymphopoiesis.
39 Notch1 activation
seems to be driven by Delta-1-expressing stro-
mal cells.
40,41
Hemopathies require the support of aber-
rant bone marrow niches 
Several hemopathies are characterized by a
pre-malignant  phase  that  progresses  to  a
malignant phase. The molecular basis of this
progression  remains  poorly  understood.  The
data in the literature suggest the likelihood of
such progression is very low and a malignant
clone can remain “stable” for years. Moreover,
in several diseases both phases are character-
ized by virtually the same genetic changes.
50,51
Taking  in  consideration  these  aspects,  it  is
legitimate  to  speculate  that  the  genetic
changes are necessary for the immortalization
of a malignant clone but insufficient to pro-
mote the progression to a malignant phase. So
other factors must take part in the progression. 
The role of the hematopoietic BM microen-
vironment in malignant progression has been
studied  extensively  and  its  importance  was
well  illustrated  in  recent,  in  vivo,  studies.
Widespread inactivation of retinoblastoma pro-
tein  (Rb)  resulted  in  myeloproliferative  dis-
ease, characterized by extramedullary hemo-
poiesis and increased mobilization and differ-
entiation of HSCs from the BM. The phenotype
was not recapitulated upon inactivation of Rb
in  HSCs  maintained  in  wild-type  environ-
ment.
52,53 Moreover,  Mx-Cre
+Pten
Δ/
Δ∆mice
develop rapid and aggressive myeloprolifera-
tion that progressed to leukemia in 4-5 weeks
post deletion. When Ptendeletion was active in
the context of a wild-type BM microenviron-
ment,  phenotypic  and  functional  HSCs  were
lost without evidence of myeloproliferation or
transformation.
54,55 Finally, BM from wild-type
mice transplanted into mice with a deficient
retinoic acid receptor γ (RARγ) microenviron-
ment  rapidly  develop  myeloproliferative  syn-
dromes  (MPS).
56 These  results  strongly  sup-
port  the  notion  that  the  progression  of  the
hemopathies is not entirely cell autonomous
but  depends  on  interactions  between  malig-
nant  cells  and  the  BM  microenvironment
(BMM). As described above, BM niches sup-
port HSC properties such as adhesion, quies-
cence,  chemotaxis  and  differentiation,  and
regulate the balance between self-renewal and
differentiation.  The  idea  outlined  in  this
review is that alteration of the two BM niches,
triggered  by  the  aberrant  expression  of  key
molecules  or  cellular  cues  between  the
endosteal and the perivascular niche, impairs
HSC  responses,  contributing  to  the  progres-
sion  of  hemopathies.  In  chronic  myeloid
leukemia  (CML),  myelodysplastic  syndromes
(MDS) and multiple myeloma (MM) circulat-
ing endothelial cells (CECs), mobilized from
the BM, share chromosomal aberrations with
the  malignant  hematopoietic  cells.
57-59 These
malignant CECs suggest the presence of aber-
rant niches in the BMM. Moreover, in B-cell
lymphomas, identical genetic aberration could
be found both in malignant cells and in the
microvascular BM endothelial cells.
60,61
Irradiation  and  chemotherapy  can  change
the  BMM  inducing  hematopoietic  and
endothelial injury and allowing cells, proteins
and cytokines to move between the vascular
and  endosteal  niches.
62 Radiation-induced
injury can also contribute to cell damage in the
microenvironment in an indirect way, as a con-
sequence of an inflammatory-type response.
63
Moreover, it has been shown that ionizing irra-
diation results in altered osteoblast differenti-
ation ability of BM mesenchymal stem cells,
destruction of the endosteal niche and conse-
quently hematopoietic injury.
64 Another possi-
bility is that malignant cells through direct and
indirect signaling can modify the features of
the vascular niche. For example, factors pro-
duced by acute lymphoblastic leukemia (ALL)
cells can induce proliferation, migration and
morphogenesis  of  human  BM  vascular
endothelial cells.
65-67 The tumor-derived factor
VEGF  and  tumor  necrosis  factor-α (TNF-α)
produced in the tumor microenvironment have
been  shown  to  modify  the  phenotype  of
endothelial cells inhibiting ICAM-1 and VCAM-
1  clustering  on  endothelial  surfaces  with
implications  for  immune-cell  trafficking.
68
Moreover, our own data suggests TNF-α is cru-
cial for the onset and also for the progression
of BM dysfunction, such as in MDS (Cachaco
et al., 2009, unpublished data).
The possible mechanisms by which aberrant
BM  niches  modify  HSCs  properties  are  dis-
cussed.
Migration/chemotaxis
Aberrant niches may promote recruitment
of malignant hematopoietic stem cells
The  perivascular  niche  expresses  unique
combinations  of  cell  adhesion  molecules
and/or chemokines capable of attracting malig-
nant HSCs. For example, it has been shown, in
vitro and in vivo, that E-selectin and SDF-1 are
expressed in vascular “hot spots” correspon-
ding  to  the  regions  that  attract  leukemic
cells.
69-71 Distruption of the interaction between
SDF-1  and  its  receptor  CXCR4  inhibits  the
homing of Nalm-6 cells, an acute lymphoblastic
leukemia  cell  line,  to  the  vascular  niche.
71
These observations raise the possibility that E-
selectin and /or SDF-1 can regulate malignant
cell  homing.  Moreover,  BM  endothelial  and
stromal cells seem involved in the migration of
ALL cells beneath BM fibroblast layers: both
cell types produce SDF-1, thereby enhancing
the adhesion molecules involved in the migra-
tion and homing of these cells to the BM.
72,73
Adhesion
Aberrant niches mediate cell-adhesion-
mediated drug resistance (CAM-DR)
It has been demonstrated, in vitro and in
vivo, that cell-cell adhesion between hemato-
poietic cells and components of the BM niches,
such as stromal cells, is involved in drug resist-
ance in AML.
74,75 AML resistance to chemother-
apy seems to be promoted by the adhesion-
dependent  secretion  of  WNT  antagonists  by
osteoblasts.
76 CAM-DR is mediated by integrins
α4 and β1, as shown in MM, CML and AML cell
lines.
77-79 Direct  correlation  has  been  found
between the expression of integrins that medi-
ate adhesion to FN and drug resistance.
Coculture of ALL cells lines with BM stroma
cells (BMSCs) resulted in reduced apoptosis
induced  by  etoposide.  In  this  stroma  model,
drug resistance required direct cell-cell con-
tact, since it could not be conferred by the addi-
tion of stromal conditioned media.
80 Moreover,
the  presence  of  BMSCs  during  treatment  of
myeloma cell lines significantly decreases the
apoptosis during exposition of mitoxantrone,
an inhibitor of topoisomerase II.
81 Notch-1 sig-
naling seems to be involved in protection of
MM from drug-induced apoptosis: overexpres-
sion of Notch-1 in Notch-1(-) myeloma cells
up-regulated  p21  and  resulted  in  protection
from drug-induced apoptosis.
82 BM niches may
provide  a  survival  advantage  for  malignant
cells following initial drug exposure and facili-
tate  the  acquisition  of  acquired  drug  resist-
ance,  determining  disease  relapse  following
chemotherapy.
Aberrant niches show impaired adhesive
capacity, leading to a loss of quiescence
and consequently to expansion of 
malignant hematopoietic stem cells 
It has been hypothesized that HSC mobiliza-
tion  results  from  impaired  adhesion  to  BM
niches,  allowing  their  migration  into  the
peripheral  blood,  spleen  and  other  extra-
medullary  sites.  This  could  explain  the
increase in circulating CD34
+ cells reported in
primary myelofibrosis (PMF) patients.
83,84
The impaired adhesion could be explained
by several mechanisms.
Altered expression of membrane adhesion
molecules and integrins. For example, HSCs of
CML  patients  have  reduced  adhesion  mole-
cules  expression  including  L-selectin,  CD44
and N-cadherin. This decrease correlates with,
in  vitro,  reduced  adhesive  capacity  of  HSCs
from CML patients.
85
A disruption of CXCR4/SDF-1 axis. In idio-
pathic  myelofibrosis  (IM)  the  constitutive
mobilization of CD34
+ cells could be the conse-
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quence  of  the  creation  of  a  proteolytic
microenvironment  within  the  BMM.  It  has
been shown that malignant cells and the BMM
produce  metalloproteinase.
86-88 Thus,  the
increased  production  of  metalloproteinase-9
might  disrupt  adhesive  interaction  between
CD34
+ HSCs and BM niches through degrada-
tion  of  SDF-1  or  cleavage  of  its  receptor
CXCR4, leading to the release of the HSCs into
the peripheral blood.
22,89
Proliferation vs. quiescence
Aberrant niches determine an imbalance
between proliferation and quiescence,
accelerating the onset and progression of
malignancy
BM cells display a different set of adhesion
molecules,  extracellular  matrix  elements,
growth factors and chemokines. Spleen fibrob-
lasts isolated from PMF patients, in contrast to
primary fibroblasts purified from the spleen of
healthy subjects, are able to support the prolif-
eration of autologous patient CD34
+ cells, but
not  that  of  their  normal  counterparts.
90
Moreover,  it  has  been  shown  that  somatic
mutations that occur in BM stromal cells, such
as p53 mutations, render these cells supportive
of ALL growth.
81 Finally, aberrant vascular nich-
es produce several factors, such as VEGF; IL-6;
granulocyte-macrophage  and  granulocyte
colony-stimulating factors, that are able to sup-
port malignant hemopoiesis.
91-93 For example, it
has been shown that coculture of AML cells
with microvascular endothelial cells increases
proliferation  and  inhibits  apoptosis  of  AML
cells.
93
Providing  self-renewing  and  proliferative
cues to malignant HSCs. ALL stromal cells reg-
ulate  self-renewal  and  proliferation  of  a
Philadelphia-chromosome  positive  (Ph
+)/VE-
cadherin
+ subpopulation of leukemia cells by
promoting the expression of VE-cadherin, sta-
bilizing β catenin and up-regulating BCR-abl
transcripts.
94 This way, due to the stromal sup-
port, malignant cells circumvent the require-
ment  of  exogenous  Wnt  signaling  for  self-
renewal. Human MM cells also become inde-
pendent of the IL-6/gp130/STAT3 survival path-
way  when  cocultured  in  the  presence  of
BMSCs.
95 This evidence confirms the idea that
BMSCs  can  provide  alternative  survival  and
proliferative signals to BM malignant cells.
Angiogenesis,  the  branching  of  new
microvessels from pre-existent blood vessels,
is kept at set point in which there is a balance
between pro- and anti-angiogenic molecules.
The angiogenic switch, unbalanced set point
in  favor  of  pro-angiogenic  molecules,  favors
the  production  of  new  microvessels.
96
Increased angiogenesis has been described in
a number of hemopathies.
97-101 The extent of
BM neo-vessel formation correlates also with
patient prognosis and these hemopathies are
sensitive  to  anti-VEGF  and  VEGF  receptor
treatments.
102-105 The expanded BM endotheli-
um may support malignant HSC growth by pro-
tecting  them  from  chemotherapy-induced
apoptosis and/or promoting their proliferation
in a paracrine way through the release of fac-
tors  such  as  G-CSF,  IL-10,  IL-6  and  vascular
endothelial growth factor-C (VEGF-C).
106,107
Aberrant vascular niches can induce 
quiescence in malignant cells playing a role
in tumor maintenance
Adhesion of malignant HSCs to BMSCs may
induce quiescence by inhibiting cell prolifera-
tion. For example, Notch-1 activation in MM
cells, after incubation on BMSCs, results in the
accumulation of the cells in G0/G1 phase of cell
cycle.
82,108 Aberrant niches may thus contribute
to  the  maintenance  of  a  malignant  pool  of
HSCs.
Differentiation
Aberrant niches can induce malignant
transformation of normal hematopoietic
stem cells
The donor cell leukemia (DCL), a hemopa-
thy following hemopoietic cell transplation, is
apparently the result of malignant transforma-
tion of normal donor hematopoietic cells in the
transplant recipient.
109 One of the hypotheses
is that the host microenvironment in which
the original malignancy developed may trigger
malignant  transformations  in  donor  cells,
favored  by  the  immunocompromised  status
after  transplantation  and  by  perturbation  of
the  host  BMM  following  multiple  rounds  of
chemotherapy. 
Studies in Drosophila Melanogaster, by Kai
et al., suggest that a vacant niche can engage
ectopic cells, normal hematopoietic and non-
hematopoietic cells, with a resultant change in
phenotype. Depending on the specific system,
it seems that non-stem cells can acquire either
a more proliferative phenotype or revert to a
stem  cell-like  condition.  These  findings
strongly support the possibility that BM niches
can contribute to hemopathies, inducing aber-
rant transformation of normal cells, including
HSCs.
110,111
Bone marrow  niches as therapeu-
tic target
Based on the idea that the BMM has a rele-
vant role in the progression of hemopathies,
novel therapeutic approaches are being devel-
oped to revert the malignant phenotype by tar-
geting  environmental  cues.  The  strategies
used until now can be summarized into three
categories. 
The  first  strategy  is  to  modify  the  niche
itself.  For  example,  Ballen  and  colleagues
have tested the hypothesis to use parathyroid
hormone (PTH) to augment the engraftment
efficiency of cord blood transplant, modifying
the receptivity of the endosteal niche.
112 PTH,
acting also on the perivascular niche, can be
used for the treatment of ischemic vascular
disease.
113 Moreover,  it  has  recently  been
shown  that  pharmacological  use  of  PTH
increases the number of HSCs mobilized into
the  peripheral  blood  for  stem  cell  harvests,
protects stem cells from repeated exposure to
cytotoxic  chemotherapy  and  expands  stem
cells in transplant recipients.
114
The  second  strategy  is  to  abrogate  the
interaction between malignant HSCs and BM
niches, by blocking their physical binding or
the growth factors secreted by the BMM. As
described  before,  the  chemokine  axis  SDF-
1/CXCR4 is involved in the retention of HSCs
within the BM. Thus, destruction of this inter-
action allows the mobilization of HSCs from
the BM to the peripheral blood. This approach
has been established clinically using G-CSF or
antibody against CXCR4.
115-117 The combination
of  both  result  in  an  enhancement  of  HSC
mobilization from the BM.
118 The proteasome
inhibitor PS-341, currently used in MM thera-
py, blocks the growth of MM cells by decreas-
ing their adherence to BMSCs and the related
protection against drug-induced apoptosis.
119
Another strategy is the inhibition of TNF-α
production  by  BM  cells,  with  a  monoclonal
antibody against the extracellular domain of
TNF-α,  called  infliximab.  Two  studies  have
investigated the use of infliximab in patients
with low-risk MDS. In both reports, the drug
showed a limited but significant activity and
no particular side-effects.
120
Another  recently  approved  therapeutic
approach  involves  inhibiting  angiogenesis;
several inhibitors of VEGF are currently used
in the treatment of different hemopathies.
104, 121
The  concept  behind  most  of  these  thera-
peutic  approaches  implies  that  to  increase
therapeutic efficacy it is necessary to use a
strategy in which the seed (malignant HSCs)
and the soil (altered BMM) must be targeted
simultaneously.
Conclusions
This paper highlights the key data demon-
strating that changes in the signals delivered
by  BM  endosteal  and/or  perivascular  niches
may lead to an impairment of survival, differ-
entiation  and  proliferation  of  HSCs.  Thus,
aberrant BM niches participating in HSC regu-
lation contribute in a crucial way to the pro-
gression  of  hemopathies.  Therefore,  the
molecular  cues  that  contribute  towards  BM
niches alteration during the onset and devel-
opment of hemopathies represent a new chal-
lenging therapeutic target.
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